Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for preventing virus infection comprising poly-gamma-glutamic acid

Inactive Publication Date: 2010-10-07
BIOLEADERS CORP +1
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007]Therefore, it is a main object of the present invention to provide a pharmaceutical composition, a functional food, and a feedstuff additive capable of inhibiting viral infection to prevent diseases, which comprise poly-gamma-glutamic acid (γ-PGA) having an infection-inhibiting effect against viruses, such as an influenza virus, inducing respiratory infection or systemic infection, as an effective ingredient.

Problems solved by technology

In some cases, it causes viral pneumonia, bacterial pneumonia and the like, which can lead to death.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for preventing virus infection comprising poly-gamma-glutamic acid
  • Composition for preventing virus infection comprising poly-gamma-glutamic acid
  • Composition for preventing virus infection comprising poly-gamma-glutamic acid

Examples

Experimental program
Comparison scheme
Effect test

example 1

Production of γ-PGA Having Ultra High Molecular Weight and Measurement of Molecular Weight Thereof

[0029]A 5 L fermenter containing a 3 L basal medium for γ-PGA production (GS medium containing 5% L-glutamic acid: 5% glucose, 1% (NH4)2SO4, 0.27% KH2PO4, 0.42% Na2HPO4.12H2O, 0.05% NaCl, 0.3% MgSO4.7H2O, pH 6.8) was inoculated with 1% culture broth of Bacillus subtilis var chungkookjang (KCTC 0697BP) and then cultured at a stirring speed of 150 rpm, an air injection rate of 1 vvm and a temperature of 37° C. for 72 hours. Cells were removed from the culture broth after completion of the culture using a filter press, thus obtaining a γ-PGA-containing sample solution.

[0030]2N sulfuric acid solution was added to the γ-PGA-containing sample solution and left to stand at 10° C. for 12 hours to collect a γ-PGA precipitate. The collected precipitate was washed with a sufficient amount of distilled water to obtain γ-PGA using a Nutsche filter. The obtained γ-PGA was measured for molecular weigh...

example 2

Toxicity Test Results Upon Oral Administration of γ-PGA

[0031]In order to examine the safety upon oral administration of γ-PGA, toxicity test upon a single oral administration of poly-gamma-glutamic acid using rats was performed by Biotoxtech Co., Ltd., an institute approved by GLP (Good Laboratory Practice) in accordance with Biotoxtech Standard Operating Procedures (SOPs), Good Laboratory Practice (GLP) regulations and test guideline.

[0032]Ten, 6-week-old male rats (159.76˜199.27 g) and 10 female rats (121.60˜138.80 g) were used, and the dose of γ-PGA administered to individual rats was calculated on the basis of body weight measured on the day of administration after fasting. All rats were fasted for about 16 hours but had free access to drinking water before administration, and then they were subjected to forceful oral administration with a single dose of γ-PGA by stomach tube using a disposable syringe (5 ml) having a catheter for oral administration attached thereto, followed b...

example 3

Immune Enhancement Effect 1 of γ-PGA Against Influenza Virus

[0035]In the present example, in order to examine an infection-inhibiting effect of poly-gamma-glutamic acid specific to avian influenza virus, the animal's death, virus proliferation, and antibody production in experimental animals infected with influenza virus, were analyzed.

(1) Preparation of Virus

[0036]As influenza virus used as a pathogen, H1N1 high pathogenicity influenza virus strain (A / Puerto Rico / 8 / 34 (H1N1)) was isolated from a mouse which was donated by Prof. Choi, Young-Ki of microbiological laboratory, College of Medicine, Chungbuk National University to amplify in Madin-Darby canine kidney (MDCK) cells to use, and 6-week-old female Balb / C mice were used as experimental animals.

[0037]Isolation of pure virus was carried out as follows.

[0038]Firstly, the isolated virus was diluted in antibiotic-containing PBS to inoculate into 10-day-old embryonated white laying hen's eggs, and then subjected to a stationary cult...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Atomic weightaaaaaaaaaa
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a pharmaceutical composition for inhibiting or preventing viral infection, which comprises an effective dose of poly-gamma-glutamic acid (γ-PGA), and more particularly, to a pharmaceutical composition, a functional food, and a feedstuff additive capable of inhibiting viral infection and preventing viral diseases, which comprise poly-gamma-glutamic acid having an infection-inhibiting effect against viruses, such as an influenza virus, inducing respiratory infection or systemic infection, as an effective ingredient.The composition containing poly-gamma-glutamic acid as an effective ingredient according to the present invention, is effective for use as an animal feedstuff additive or a pharmaceutical agent for preventing influenza virus infection and various viral diseases as well as a pharmaceutical composition and a functional food to promote human health.

Description

TECHNICAL FIELD[0001]The present invention relates to a pharmaceutical composition for inhibiting or preventing viral infection, which comprises an effective dose of poly-gamma-glutamic acid, and more particularly, to a pharmaceutical composition, a functional food, and a feedstuff additive capable of inhibiting viral infection and preventing viral diseases, which comprise poly-gamma-glutamic acid having an infection-inhibiting effect against viruses, such as an influenza virus, inducing respiratory infection or systemic infection, as an effective ingredient.BACKGROUND ART[0002]Influenza virus belongs to the Orthomyxoviridae family, and has 8 RNA fragments, PB2, PB1, PA, HA, NP, NA, M and NS. It is basically composed of a virus envelope having lipid bilayer structure, and an interior nucleocapsid surrounded by external glycoprotein or RNA combined with nucleoprotein. The internal layer of a virus envelope is mainly composed of matrix proteins, and the external layer thereof is compo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/16A61P31/12
CPCA61K38/164A61K31/785A61P11/00A61P31/12A61P31/16
Inventor SUNG, MOON-HEEKIM, CHUL JOONGPOO, HARYOUNGCHOI, YOUNG-KILEE, IL HANYOO, DAI-WON
Owner BIOLEADERS CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com